This company listing is no longer active
D89 Stock Overview
A biotechnology company, focuses on the discovery, development, and commercialization of anti infectives in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Destiny Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.048 |
| 52 Week High | €0.93 |
| 52 Week Low | €0.021 |
| Beta | 0.22 |
| 1 Month Change | 61.02% |
| 3 Month Change | -74.18% |
| 1 Year Change | -91.20% |
| 3 Year Change | -96.70% |
| 5 Year Change | n/a |
| Change since IPO | -95.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| D89 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 50.8% | -3.5% | -2.0% |
| 1Y | -91.2% | -14.7% | 6.9% |
Return vs Industry: D89 underperformed the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: D89 underperformed the German Market which returned -0.8% over the past year.
Price Volatility
| D89 volatility | |
|---|---|
| D89 Average Weekly Movement | 35.9% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: D89's share price has been volatile over the past 3 months.
Volatility Over Time: D89's weekly volatility has increased from 21% to 36% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 15 | Chris Tovey | www.destinypharma.com |
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of anti infectives in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections.
Destiny Pharma plc Fundamentals Summary
| D89 fundamental statistics | |
|---|---|
| Market cap | €4.55m |
| Earnings (TTM) | -€6.59m |
| Revenue (TTM) | €968.87k |
4.7x
P/S Ratio-0.7x
P/E RatioIs D89 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D89 income statement (TTM) | |
|---|---|
| Revenue | UK£831.55k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£831.55k |
| Other Expenses | UK£6.49m |
| Earnings | -UK£5.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.059 |
| Gross Margin | 100.00% |
| Net Profit Margin | -680.30% |
| Debt/Equity Ratio | 0% |
How did D89 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/13 13:35 |
| End of Day Share Price | 2024/08/14 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Destiny Pharma plc is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian White | Cantor Fitzgerald Europe |
| Nathaniel Calloway | Edison Investment Research |
| Brian White | Shore Capital Group Ltd |